Unicycive Therapeutics, Inc. Faces Legal Scrutiny from Shareholders
The Gross Law Firm is bringing attention to a significant class action lawsuit that has been filed on behalf of shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This legal motion arises from allegations of misleading information circulated by the company's executives, which may have led to financial losses for investors.
Details of the Class Action
This class action encompasses the period from March 29, 2024, to June 27, 2025, during which Unicycive is accused of making false and misleading statements about its operational readiness and product compliance. The firm is urging shareholders who purchased shares of UNCY during this timeline to voice their concerns and consider involvement in this lawsuit.
Why Get Involved?
Shareholders who register do not need to serve as lead plaintiffs in order to participate in the potential recovery process. By engaging in this class action, investors can ensure their interests are represented while also receiving updates on the case’s progress.
Allegations Against Unicycive Therapeutics
The complaint outlines that Unicycive's management inadequately represented the company's capabilities to meet FDA manufacturing compliance standards. Furthermore, there are claims that the prospects for the oxylanthanum carbonate new drug application were overly optimistic, suggesting that public statements made by the company contained significant inaccuracies. These omissions and misstatements may have led to an inflated stock price and subsequent investor losses.
Important Deadlines for Shareholders
All interested shareholders are encouraged to act swiftly, as the deadline to register for participation in this class action is October 14, 2025. It is essential for investors to be proactive in safeguarding their rights in light of these serious allegations.
Next Steps for Investors
Once a shareholder registers, they will gain access to an exclusive portfolio monitoring service that offers continuous updates about the litigation process. This service enables investors to stay well-informed as the case progresses, ensuring that they are aware of all developments.
Why Choose The Gross Law Firm?
The Gross Law Firm is dedicated to representing the rights of investors who have faced losses due to deception and unethical business conduct. Their commitment extends to maintaining a high standard of corporate accountability, urging companies to operate with integrity and transparency. With extensive experience in class action lawsuits, they offer robust support for investors affected by misleading corporate practices.
Contact Information
Investors seeking further information can reach out to the Gross Law Firm:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the nature of the class action lawsuit?
The lawsuit focuses on allegations that Unicycive Therapeutics issued misleading statements that may have caused financial harm to shareholders.
Who can participate in the class action?
Shareholders who purchased shares of UNCY between March 29, 2024, and June 27, 2025, are eligible to participate.
What are the potential outcomes of the lawsuit?
While outcomes are uncertain, the goal is to seek recovery for those who suffered losses due to the alleged misinformation.
What should I do if I purchased shares during the class period?
Shareholders are encouraged to register for the class action to protect their rights and stay informed about the case's developments.
Why is it important to act quickly?
The deadline to register is October 14, 2025, and acting promptly ensures that investors can be included in the case.
